<DOC>
	<DOCNO>NCT00569309</DOCNO>
	<brief_summary>RATIONALE : Vaccines may help body build effective immune response kill cancer cell . Giving vaccine therapy autologous stem cell transplant may kill cancer cell remain transplant . PURPOSE : This clinical trial study well vaccine therapy work treat patient undergone autologous stem cell transplant high-risk lymphoma multiple myeloma .</brief_summary>
	<brief_title>Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl High-Risk Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess immune reconstitution measure response pneumococcal polyvalent vaccine , NK-cell activity autologous lymphoblastoid cell line , cytomegalovirus Epstein-Barr virus tetramer responses patient undergone autologous hematopoietic stem cell transplantation high-risk lymphoma multiple myeloma . Secondary - Assess absolute number circulate regulatory T-cells function cell measure expression TGFβ interleukin-10 ( IL-10 ) . - Evaluate effect condition therapy quality life , include functional status , fatigue , depression , patient . - Correlate quality life inflammatory cytokine production peripheral blood monocyte specify time point . - Provide baseline immune reconstitution quality life pilot data comparison future post-transplant immunotherapy trial . OUTLINE : Patients receive pneumococcal polyvalent vaccine intramuscularly week 9 , 17 , 25 autologous hematopoietic stem cell transplantation . Blood sample collect periodically correlative immunological study . Quality life ( QOL ) assess periodically use QOL short form ( SF-36 , 4-week version ) , Center Epidemiologic Studies Depression scale ( CES-D ) , Multidimensional Fatigue Symptom Inventory ( MFSI-30 ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma OR follow highrisk lymphoma : Diffuse large Bcell lymphoma meeting follow criterion : Failed induction therapy respond salvage therapy Relapsed &lt; 1 year completion induction therapy Elevated lactic dehydrogenase ( LDH ) relapse Stage III IV disease relapse Positive PET scan induction salvage therapy Age 60 75 year Follicular lymphoma meeting follow criterion : Progressive disease two prior regimen Transformed aggressive diffuse large Bcell lymphoma still chemotherapy sensitive Not consider good candidate allogeneic stem cell transplantation Hodgkin lymphoma meeting follow criterion : Primary refractory disease Relapsed &lt; 1 year completion induction therapy Relapsed PET positive disease salvage therapy Relapsed refractory disease consider good candidate allogeneic stem cell transplantation Mantle cell lymphoma meet follow criterion : Chemotherapy sensitive disease induction therapy Chemotherapy sensitive relapse disease consider good candidate allogeneic stem cell transplantation Tcell nonHodgkin lymphoma ( NHL ) meeting follow criterion : Peripheral Tcell lymphoma , otherwise specified meeting least one follow criterion : High LDH diagnosis Marrow involvement diagnosis Age &gt; 60 year diagnosis Low platelet count diagnosis Chemotherapy sensitive relapse disease Angioimmunoblastic lymphadenopathy dysproteinemia ALKnegative anaplastic NHL Enteropathyassociated Tcell NHL Stage III IV NK/Tcell NHL diagnosis NKblastic NHL Has undergone autologous hematopoietic stem cell transplantation receive 200 mg/m² melphalan ( multiple myeloma ) OR BEAM chemotherapy comprise carmustine , etoposide , cytarabine , methotrexate ( highrisk lymphoma ) conditioning therapy PATIENT CHARACTERISTICS : ECOG WHO performance status 02 ANC ≥ 1,000/μL Platelet count ≥ 75,000/μL Total bilirubin ≤ 1.5 mg/dL Alkaline phosphatase ≤ 2 time upper limit normal ( ULN ) AST ALT ≤ 2 time ULN Not pregnant nursing No severe uncontrolled systemic illness No `` currently active '' second malignancy , nonmelanoma skin cancer carcinoma situ cervix Patients consider `` currently active '' malignancy complete therapy malignancy , disease free malignancy &gt; 5 year , consider physician &lt; 30 % risk relapse No significant history uncontrolled cardiac disease include , limited , follow : Uncontrolled hypertension Unstable angina Recent myocardial infarction ( within past 6 month ) Uncontrolled congestive heart failure No active bacterial , fungal , viral infection No known HIV infection active hepatitis B and/or hepatitis C infection No medical condition , include mental illness substance abuse , deem investigator ( ) likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation study result PRIOR CONCURRENT THERAPY : No concurrent biologic therapy , chemotherapy , antineoplastic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
</DOC>